LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Chemical and olfactometric inventory of gaseous spot vents in Mt. Amiata volcanic-geothermal area (Italy).

    Invernizzi, Marzio / Scolieri, Giacomo Domenico / Tagliaferri, Francesca / Bettini, Alessandro / Cinci, Marcello / Lenzi, Alessandro / Sironi, Selena

    The Science of the total environment

    2024  Volume 931, Page(s) 172607

    Abstract: Geothermal areas are typically characterised by the presence of gases and odours in the background atmosphere, stemming from natural emissions and possible mining exploitation of the area. This study presents the first olfactometric investigation of ... ...

    Abstract Geothermal areas are typically characterised by the presence of gases and odours in the background atmosphere, stemming from natural emissions and possible mining exploitation of the area. This study presents the first olfactometric investigation of endogenous gas emissions from natural and archaeo-industrial vents in a geothermal area. Mt. Amiata is known for its complex geology and historical cinnabar mining. This study offers an inventory of spot gas emissions, not only in terms of odour and chemical concentration but also including flux data, a ground-breaking achievement in this field. The primary challenge of this investigation was estimating the emitted flow from ground holes or mine entrances, posing the risk of hazardous anoxic conditions. To address this challenge, an innovative and adaptive approach was adopted. The main breakthrough method involved the adaptation of a balometer, typically employed for indoor ventilation systems, to measure the flow of endogenous gases. Field surveys revealed odour concentrations that can exceed 10
    Language English
    Publishing date 2024-04-25
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 121506-1
    ISSN 1879-1026 ; 0048-9697
    ISSN (online) 1879-1026
    ISSN 0048-9697
    DOI 10.1016/j.scitotenv.2024.172607
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia.

    Lenzi, Alessandro / Maltinti, Elisabetta / Poggi, Enzo / Fabrizio, Lazzerini / Coli, Elisabetta

    Clinical neuropharmacology

    2003  Volume 26, Issue 6, Page(s) 317–321

    Abstract: We aimed to determine whether the cholinesterase inhibitor rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), would improve quality of life and cognitive function in 16 clinically stable subjects affected by ... ...

    Abstract We aimed to determine whether the cholinesterase inhibitor rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), would improve quality of life and cognitive function in 16 clinically stable subjects affected by schizophrenia in the residual phase. Study subjects began rivastigmine treatment at a dose of 1.5 mg bid. This dose was escalated at monthly intervals in increments of 1.5 mg bid to a maximum of 6 mg bid. All subjects were followed for 12 months. Quality of life was assessed using the Satisfaction with Life Domains Scale (SLDS, a self-report scale containing 10 "satisfaction" items); cognitive function, attentional function, and aspects of learning and memory were evaluated using common neuropsychological tests. Psychopathology was evaluated by means of the Brief Psychiatric Rating Scale (BPRS). Rivastigmine treatment resulted in significant improvements in quality of life, which were paralleled by significant improvements in cognitive function, learning and memory, and trends for improvement in attention. The BPRS factor "anergia" showed significant improvement, while low baseline scores in other psychotic factors did not permit further improvements. There were no reports of nausea or vomiting. In conclusion, rivastigmine significantly improved quality of life in subjects with schizophrenia. These benefits may relate to the drug's effects on cognitive deficits and negative symptoms associated with the condition.
    MeSH term(s) Adolescent ; Adult ; Carbamates/adverse effects ; Carbamates/therapeutic use ; Cognition/drug effects ; Female ; Humans ; Male ; Middle Aged ; Neuroprotective Agents/adverse effects ; Neuroprotective Agents/therapeutic use ; Phenylcarbamates ; Psychiatric Status Rating Scales ; Quality of Life/psychology ; Rivastigmine ; Schizophrenia/drug therapy ; Schizophrenic Psychology ; Treatment Outcome
    Chemical Substances Carbamates ; Neuroprotective Agents ; Phenylcarbamates ; Rivastigmine (PKI06M3IW0)
    Language English
    Publishing date 2003-08-15
    Publishing country United States
    Document type Clinical Trial ; Journal Article
    ZDB-ID 199293-4
    ISSN 1537-162X ; 0362-5664
    ISSN (online) 1537-162X
    ISSN 0362-5664
    DOI 10.1097/00002826-200311000-00011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top